Christina Washington

Also affiliated with Oklahoma State University Oklahoma City, University of Oklahoma Health Sciences Center, Clark Atlanta University, University of Oklahoma

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial”.

Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3877

N/A

0DataRank · unranked

8 citations

Austin Miller, Peter G. Rose, Mariam AlHilli, Christina Washington, Veena S. John +15 more

Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice review

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.11.020

N/A

0DataRank · unranked

0 citations

Bhavana Pothuri, Karen A. Cadoo, Yvette Drew, Rachel Miller-Garcia, Deborah K. Armstrong +2 more